International research group led by Professor Chen has developed a new generation of potentially safer and more cost-effective therapies against West Nile virus etc, and other pathogens.

Scientists applied therapy based on monoclonal antibodies and their derivatives.

For the purposes of the study monoclonal antibodies are derived from tobacco plants, which is promising to change the image of the plant, which are believed to cause cancer of the lung.

The antibodies are directed against proteins located on the surface of the virus.

The main objective of the study is to create innovative, sustainable and affordable therapy that also be a cheap solution to combat the global threat of West Nile virus.

One approach is the development of therapeutic antibodies that bind to receptors which may help of the monoclonal antibodies to cross into the brain.

In a new study, the researchers developed a half-dozen new options that could assist in the implementation monoclonal antibodies that can be effectively targeted to the brain and to neutralize the dangerous virus.

The final results of the study show 90% success in preventing letalnit development in experimental conditions.

This is the first case of such an effect, leading to the neutralization of the virus.

Dr. Chen results are motivating the development of plant-based therapy that dramatically reduce the cost of commercial production of monoclonal antibodies.

The virus is spread by infected mosquitoes and affect the central nervous system.

Infection can cause serious, life-altering and even fatal disease.

Until now, however, is not available or effective drug therapy for dealing with infection.

In an attempt to better understand why some viruses like influenza, Ebola and West Nile virus so lethal, a team of U.S. researchers believe to model the response of the body to viral pathogens.

The study, which will be led by Yoshiro Kavaoka - professor of patho-biological sciences and an expert on influenza and Ebola viruses from Washington University, will be funded with 18.3 million dollars from the National Institutes of Health USA. Its purpose is to study the detailed molecular mechanisms of infection of the cell, the cell response to a virus, and the interaction - host.

U.S. government - the main source of funding for the entire project, hopes all this lead to the creation of a new generation of antiviral drugs against some of the most dangerous pathogens. This is extremely important because against Ebola and West Nile virus are currently no approved drugs and those against influenza quickly lose their effectiveness.

The design of the test involves the measurement of a wide variety of parameters - such as specific to the virus and those specific to the host. Measurements will be made using the so-called. high-screened, wherein the complex machinery made ​​thousand measurements per second.

Advantage of study of three different pathogens - influenza viruses, and Ebola WNV is that they have different target cells and organs in the body. This systematic approach allows identification of common and different pathways and mediators in the course of various infections. Common mediators are potential targets for future broad products, i.e. those having efficacy against a number of pathogens. Unique key for an infection metabolites target for future narrow-spectrum drugs.

Buy West Nile Virus (WNV) products from Gentaur